SCHEMBL4825661

SCHEMBL4825661

NC1c2ccsc2N=CN1c1ccc(NC(=O)Nc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ HTT P42858 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ KDR P35968 9/20 0.48
▸ AURKA O14965 1/20 0.48
▸ AURKB Q96GD4 1/20 0.48
▸ TP53 P04637 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ CDK8 P49336 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ BRAF P15056 1/20 0.45
▸ MAPK14 Q16539 1/20 0.45
▸ TNNI3K Q59H18 1/20 0.45
▸ EPHA3 P29320 1/20 0.44
▸ EPHB4 P54760 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826378 0.86 CA12 (0.49) KDRAURKAAURKBCDK8MAPK14
SCHEMBL4831099 0.86 MAPT (0.47) MAPTMEN1KMT2AKDRAURKA
SCHEMBL4825817 0.86 PKM (0.45) MAPTMEN1KMT2AKDRAURKA
SCHEMBL4833818 0.82 RET (0.41) MAPTKDRTP53LMNASMN1; SMN2
SCHEMBL4833483 0.81 KMT2A (0.48) MAPTMEN1HTTKMT2ARAB9A
SCHEMBL4836049 0.81 PSEN1 (0.46) MAPTMEN1HTTKMT2ALMNA
SCHEMBL4836423 0.80 KCNJ5 (0.36) MAPTMEN1HTTKMT2ALMNA
SCHEMBL4828962 0.80 CSF1R (0.39) HTTAURKBLMNA
SCHEMBL4825889 0.79 THRB (0.41) KDRTP53EPHB4IDH2
SCHEMBL4831067 0.78 DDX3X (0.44) MAPTMEN1HTTKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP claimed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK MAPT 2499/4885MEN1 303/4885HTT 2961/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR MAPT 2424/4885MEN1 1454/4885HTT 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback